Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience. - Wikidata - wikimedia - TriplyDB

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.

http://www.wikidata.org/entity/Q34669824

about

Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements Challenges in the clinical utility of the serum test for HER2 ECD Advances in the Molecular Analysis of Breast Cancer: Pathway Toward Personalized Medicine Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event Molecular mechanisms of antigen retrieval: antigen retrieval reverses steric interference caused by formalin-induced cross-links.Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research Real-world data in the molecular era-finding the reality in the real world.Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay HER2/neu in systemic therapy for women with breast cancer: a systematic review.Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybrid Experimental validation of peptide immunohistochemistry controls.Feasibility study for collection of HER2 data by National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program central cancer registries.HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens A common copy-number breakpoint of ERBB2 amplification in breast cancer colocalizes with a complex block of segmental duplications.HER2/neu Testing In 432 Consecutive Breast Cancer Cases using FISH and IHC - A Comparative Study.The validation of a novel method combining both HER2 immunohistochemistry and HER2 dual-colour silver in situ hybridization on one slide for gastric carcinoma testing.In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients Integrative analysis of copy number and gene expression in breast cancer using formalin-fixed paraffin-embedded core biopsy tissue: a feasibility study.Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer.Image analysis as an adjunct to manual HER-2 immunohistochemical review: a diagnostic tool to standardize interpretation Automated analysis of fluorescent in situ hybridization (FISH) labeled genetic biomarkers in assisting cervical cancer diagnosis.Optical fiber-based in vivo quantification of growth factor receptors.Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers.Biologic and therapeutic role of HER2 in cancer.Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor Specimens.Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer.The epidermal growth factor receptor family in breast cancer.Predictive biomarkers and companion diagnostics. The future of immunohistochemistry: "in situ proteomics," or just a "stain"?Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer Understanding the economic value of molecular diagnostic tests: case studies and lessons learned.Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer Genomic testing and therapies for breast cancer in clinical practice.Trastuzumab use in breast cancer: clinical issues.Antibody-based therapeutics in oncology.The clinical evaluation of HER-2 status: which test to use?Quality assessment of HER2 testing by monitoring of positivity rates Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival.Best Practice No 176: Updated recommendations for HER2 testing in the UK Use of tissue microarray for interlaboratory validation of HER2 immunocytochemical and FISH testing

P2860

Q24673038-A5D3002F-0583-4858-87CC-C7D6CFD9307A Q26861754-2702229B-F3DE-4E7F-9937-762CE3A9DA48 Q27001994-494A116C-A064-4A7D-A0B8-F94451C3D913 Q28245213-5BB5DF66-D512-47B5-AACF-0E02BC4FE6D6 Q30382246-713DBF65-B634-4D60-B472-B5C33675B92A Q30419845-9591DA1A-1ED9-451A-B1A3-12DC7F447D5B Q31023009-43836F24-43AC-4253-9A00-7CB83D1199C9 Q31034429-7DA89D47-12AC-4C35-A547-E60A1491F0DE Q33291068-8847F2AB-D70A-43A7-BC18-6449FA6BD381 Q33378811-D8F6AD85-C01A-4AB9-9045-9ACD3C1EF942 Q33392529-99D9D660-BACD-4CF2-8804-BA91BE4AF5D2 Q33522516-D77177F1-1263-4F0D-820F-1C6C4B7B726A Q33711632-6A91089C-A40B-4B72-BAF8-24F2AFF704A3 Q33739397-A143A5DC-0E19-45AE-96B0-E96A04C85931 Q33741544-C80EAC16-867B-4C40-AD45-F202659B683C Q33764191-CC72D58F-5C9E-4033-A64B-DEB2C5B2C853 Q33812042-C10DFEEB-088A-48A4-AF87-B6CF8D798552 Q33896397-B75FE072-F781-4CD0-A6DC-AEFFB0C2A9C4 Q33990934-09E5A89C-AC18-4079-9D90-444865C6C1B8 Q34044859-D29699C8-2448-467A-B49A-8AE3278D855E Q34046577-00CB8FA1-FA5C-42C0-9FF2-389D471D4A93 Q34226408-45F666A6-4A45-46B1-AF18-F4C6F4112A59 Q34248282-3B610628-E074-4D09-8878-1C5F2E4396EF Q34267775-75E04364-19BA-49E0-90FB-1DEE23D3D784 Q34342079-5A4D4CBB-57DD-4D5D-9631-3EDFA5576DBA Q34344198-B362A19F-21C6-426A-906A-295037F16622 Q34363400-A637F48E-126A-4403-937F-A8C3AB03A57F Q34434447-19FBEBB2-D188-4C14-91F0-FE3DA3588B65 Q34511787-9512D33A-6065-4791-A774-35774E244C23 Q34608705-E994DA41-0B50-4DBF-8071-B4651BDAF210 Q34664129-AD98647A-B98A-41DC-B00B-624C9A4801A7 Q34967515-70210224-D7D3-4E2D-8142-19E271BA8FC5 Q34974164-58C0A4CC-1DBB-4419-8BFA-73D89E6B7AA2 Q35039495-A01271CA-3149-4DA5-A48D-490A17C24AA3 Q35070445-3AF51E34-DE8F-47FF-B8AB-6B421E18E974 Q35084775-602E74F7-C86D-471F-9D30-B5BCD408D81E Q35183522-BE6C5C67-CEA3-4B73-BC85-B40D08D309FC Q35343184-B2B08BB4-ED7C-4E0D-9AB9-B53BBA3432F1 Q35587451-12784F14-20B0-4021-A3F9-1F7D166818CD Q35588100-8C72336B-BA0E-4893-B2D4-9E2926657E7E

P2860

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.

http://www.wikidata.org/entity/Q34669824

description

2002 nî lūn-bûn

@nan

2002 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Real-world performance of HER2 ...... and Bowel Project experience.

@ast

Real-world performance of HER2 ...... and Bowel Project experience.

@en

Real-world performance of HER2 ...... and Bowel Project experience.

@nl

type

label

Real-world performance of HER2 ...... and Bowel Project experience.

@ast

Real-world performance of HER2 ...... and Bowel Project experience.

@en

Real-world performance of HER2 ...... and Bowel Project experience.

@nl

prefLabel

Real-world performance of HER2 ...... and Bowel Project experience.

@ast

Real-world performance of HER2 ...... and Bowel Project experience.

@en

Real-world performance of HER2 ...... and Bowel Project experience.

@nl

P1433

Q34669824-BEBAC648-BF5A-416D-AFB0-C48F7BE5C3C7

P1476

Q34669824-B8A0A837-B1BC-46D4-81CB-23920B8EBF45

P2093

Q34669824-3E989FF7-9DDE-4F42-8B9F-3E05F66FE30E

Q34669824-57EEA5E5-E4C7-4168-9421-2FC1F5BC9858

Q34669824-629531D5-F9C2-4D06-8A03-864246DA0D21

Q34669824-64C33625-0049-4714-9B41-70EC6C99695E

Q34669824-68135116-201F-4F02-9671-D34F0E806499

Q34669824-8B8F011E-7CFD-4532-A6ED-397CA295C583

Q34669824-B1FCFEDE-9D10-4E4C-8BC3-93C3D766778B

Q34669824-BBE46660-EB4E-4358-9319-127C206BE22A

Q34669824-D1618872-9C18-4872-9A59-C4F45DE2DEE6

Q34669824-DDDE6AD0-02A3-4CF1-9763-6D55C5E39C0E

P2860

Q34669824-0809928E-E9F9-4547-9248-2320C9CF3A8E

Q34669824-3D5078BF-1567-4EB0-9134-9BE1884BE2F6

Q34669824-72430458-AD32-4D24-BB17-7237255641CA

Q34669824-C2ABED3C-D999-40D3-BD95-CE3FB7EDFC88

Q34669824-C7B8A45C-307A-4F40-884E-698E294EF655

Q34669824-C870FB29-B3CF-43FC-947E-CFE2FFFDED53

Q34669824-CFF85D15-5AFD-48CB-936A-4C83ABBBF1AB

Q34669824-F43BD80E-427A-40A1-93BA-DC78AC8C3E2E

P304

Q34669824-C9B465F2-A4AE-4368-86CB-2A9A9C6D58F3

P31

Q34669824-CCE8D523-E10E-4E85-9852-961AA63A3BCA

P356

Q34669824-BE23C0F1-45BC-4051-97AC-BF345F6E4896

P407

Q34669824-72C208A6-05F5-4430-9E26-FD5DA60DE4FF

P433

Q34669824-B46185C1-835E-42A8-8729-EA935E6FFD02

P478

Q34669824-D7E0A699-3E98-4B98-9EA6-AC7872EB8ACD

P50

Q34669824-8EAB6A34-5DC1-4A77-AAB9-5F3482D60664

P577

Q34669824-512D0B64-DFD6-4ECB-94FB-CBE507F4F7EA

P5875

Q34669824-CD22AC16-3A55-4FB0-986B-560245669483

P698

Q34669824-505858A5-9822-416E-B319-BC812A55474B

P356

P1433

Journal of the National Cancer Institute

P1476

Real-world performance of HER2 ...... and Bowel Project experience.

@en

P2093

Ann Brown

http://www.w3.org/2001/XMLSchema#string

D Lawrence Wickerham

http://www.w3.org/2001/XMLSchema#string

Elizabeth Tan-Chiu

http://www.w3.org/2001/XMLSchema#string

Greg Yothers

http://www.w3.org/2001/XMLSchema#string

John Bryant

http://www.w3.org/2001/XMLSchema#string

Kyeongmee Park

http://www.w3.org/2001/XMLSchema#string

Norman Wolmark

http://www.w3.org/2001/XMLSchema#string

Roy Smith

http://www.w3.org/2001/XMLSchema#string

Soonmyung Paik

http://www.w3.org/2001/XMLSchema#string

Steve Anderson

http://www.w3.org/2001/XMLSchema#string

P2860

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use

Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization.

Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma.

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.

HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma.

HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach.

HER2--a discussion of testing approaches in the USA.

P304

852-854

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/94.11.852

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

94

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11325730

http://www.w3.org/2001/XMLSchema#string

P698

12048273

http://www.w3.org/2001/XMLSchema#string